Form 4: Enanta CBO Brendan Luu Forfeits Shares for Tax

Enanta Pharmaceuticals' Chief Business Officer, Brendan Luu, forfeited 498 shares of common stock to cover tax obligations related to a restricted stock unit settlement.

Summary

• Brendan Luu, Chief Business Officer of Enanta Pharmaceuticals Inc. (ENTA), reported a transaction involving the company's common stock.
• On December 1, 2025, Luu disposed of 498 shares of ENTA common stock.
• This disposition was a forfeiture (Transaction Code 'F') to cover withholding taxes due as a result of the settlement of a portion of a restricted stock unit award.
• The shares were valued at $14.12 per share for the purpose of this tax withholding.
• Following this transaction, Luu directly beneficially owns 39,723 shares of ENTA common stock.
• The original restricted stock unit award, which led to this settlement and tax forfeiture, was granted on November 19, 2021.

Sentiment

Score: 5

Explanation: Neutral. This is a routine, non-discretionary transaction for tax purposes related to executive compensation and does not reflect a positive or negative sentiment towards the company or its prospects.

Future Outlook

NA

Industry Context

This is a routine insider transaction related to compensation and tax obligations, which typically has no direct bearing on broader industry trends or competitive landscape for Enanta Pharmaceuticals.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine, non-discretionary tax-related transaction by an executive, not indicative of a change in company fundamentals or strategy.
• No direct impact on employees, customers, suppliers, or creditors.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary transaction where an executive forfeited shares to cover tax liabilities from a restricted stock unit settlement. Such transactions are common and do not typically signal any change in the company's operational performance, financial health, or future prospects. Therefore, it provides no new information to warrant a change in investment recommendation; a 'hold' stance is maintained based on existing fundamentals.

Keywords

Enanta Pharmaceuticals, ENTA, Brendan Luu, Insider Transaction, Form 4, Stock Forfeiture, Restricted Stock Units, Tax Withholding, Chief Business Officer